Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 03, 2018 08:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Announces First-of-their-kind Programs to Improve Patient Access to LUXTURNA™ (voretigene neparvovec-rzyl), a One-time Gene Therapy Treatment

Company offers outcomes-based rebates and an innovative contracting model that support patient access in the U.S. while aiming to reduce risk and financial burden for payers and treatment centers ...
January 02, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Participate in Multiple Conferences in January

PHILADELPHIA, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
December 19, 2017 15:05 ET | Source: Spark Therapeutics, Inc.

FDA Approves Spark Therapeutics’ LUXTURNA™ (voretigene neparvovec-rzyl), a One-time Gene Therapy for Patients with Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy

LUXTURNA is first gene therapy for a genetic disease, first and only pharmacologic treatment for an inherited retinal disease (IRD) and first adeno-associated virus (AAV) vector gene therapy approved...
December 11, 2017 07:45 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Presents Preliminary Data on Investigational SPK-8011 Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting and Exposition

PHILADELPHIA, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
December 11, 2017 07:00 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics and Pfizer Announce Longer-term Preliminary Data Showing Consistent and Sustained Factor IX Levels in Hemophilia B at 59th American Society of Hematology (ASH) Annual Meeting and Exposition

Data include eleventh participant in the trial Annualized bleeding rate (ABR) for all 11 participants was reduced by 97 percent, while annualized infusion rate (AIR) was reduced 99 percent as of...
December 06, 2017 17:00 ET | Source: Spark Therapeutics, Inc.; Pfizer Inc.

Spark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B

PHILADELPHIA and NEW YORK, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease,...
December 05, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Announces Multiple Presentations on Updated Hemophilia A and Hemophilia B Phase 1/2 Clinical Trials at 59th American Society of Hematology Annual Meeting and Exposition

PHILADELPHIA, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
November 10, 2017 17:05 ET | Source: Spark Therapeutics, Inc.

Three-year Follow-up Phase 3 Data Provide Additional Information on Efficacy, Durability and Safety of Investigational LUXTURNA™ (voretigene neparvovec) in Patients with Biallelic RPE65-mediated Inherited Retinal Disease

PHILADELPHIA, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
November 07, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Reports Third Quarter 2017 Financial Results and Recent Business Progress

PHILADELPHIA, Pa., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease,...
November 07, 2017 07:15 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics and Pfizer Amend License Agreement for Investigational SPK-9001 in Hemophilia B

PHILADELPHIA and NEW YORK, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE) and Pfizer Inc. (NYSE:PFE) today announced they have entered into an amendment to their license...